Patterns of cannabis use among patients with multiple sclerosis
Abstract
To estimate the patterns and prevalence of cannabis use among patients with multiple sclerosis (MS), 220 patients were surveyed in Halifax, Nova Scotia. Seventy-two subjects (36%) reported ever having used cannabis for any purpose; 29 respondents (14%) reported continuing use of cannabis for symptom treatment. Medical cannabis use was associated with male gender, tobacco use, and recreational cannabis use. The symptoms reported by medical cannabis users to be most effectively relieved were stress, sleep, mood, stiffness/spasm, and pain.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Three cross-sectional studies also report antidepressant effects of CBM.
“Three cross-sectional studies also report antidepressant effects of CBM.82,97,98”
From Clinical Practice Guidelines for Cannabis and Cannabinoid-Based Medicines in the Management of Chronic Pain and Co-Occurring Conditions (2024) · cites this paper as [82]
Cites
Zajicek, J., Fox, P., Sanders, H., Wright, D., Vickery, J., Nunn, A., & Thompson, A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14738-1 · Cited by 827 · see citing works
The perceived effects of smoked cannabis on patients with multiple sclerosis.
Consroe, P., Musty, R., Rein, J. A., Tillery, W., & Pertwee, R. (1997) · European Neurology · doi:10.1159/000112901 · Cited by 329 · see citing works
Safety, tolerability, and efficacy of orally administered cannabinoids in MS
Killestein, J., Hoogervorst, E. L. J., Reif, M., Kalkers, N. F., Loenen, A. C. V., Staats, P. G. M., Gorter, R. W., Uitdehaag, B. M. J., & Polman, C. H. (2002) · Neurology · doi:10.1212/wnl.58.9.1404 · Cited by 209 · see citing works
Cannabis use for chronic non-cancer pain: results of a prospective survey
Ware, M. A., Doyle, C. R., Woods, R., Lynch, M. E., & Clark, A. J. (2003) · Pain · doi:10.1016/s0304-3959(02)00400-1 · Cited by 185 · see citing works
Self-citationSafety, tolerability, and efficacy of orally administered cannabinoids in MS
Russo, E. B. (2003) · Neurology · doi:10.1212/wnl.60.4.729-a · Cited by 184 · see citing works
Delta-9-THC in the Treatment of Spasticity Associated with Multiple Sclerosis
Ungerleider, J. T., Andyrsiak, T., Fairbanks, L. A., Ellison, G. W., & Myers, L. W. (1988) · Advances in Alcohol & Substance Abuse · doi:10.1300/j251v07n01_04 · Cited by 165 · see citing works
Effect of cannabinoids on spasticity and ataxia in multiple sclerosis
Meinck, H. ‐., Sch�nle, P. W., & Conrad, B. (1989) · Journal of Neurology · doi:10.1007/bf00314410 · Cited by 131 · see citing works
Greenberg, H. S., Werness, S. A. S., Pugh, J. E., Andrus, R. O., Anderson, D. J., & Domino, E. F. (1994) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1994.33 · Cited by 128 · see citing works
The Pharmacohistory of Cannabis Sativa
Mechoulam, R. (2019) · Chapman & Hall/CRC eBooks · doi:10.1201/9780429260667-1 · Cited by 92 · see citing works
Suppression of pendular nystagmus by smoking cannabis in a patient with multiple sclerosis
Schon, F., Hart, P. E., Hodgson, T. L., Pambakian, A., Ruprah, M., Williamson, E. M., & Christopher Kennard, C. (1999) · Neurology · doi:10.1212/wnl.53.9.2209-a · Cited by 82 · see citing works
Cannabis Use as Described by People with Multiple Sclerosis
Page, S. A., Verhoef, M. J., Stebbins, R. A., Metz, L. M., & Levy, J. C. (2003) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100002584 · Cited by 81 · see citing works
Long-term follow-up of aneurysms developed during extracranial internal carotid artery dissection
Meairs, S. P., & Hennerici, M. G. (2000) · Neurology · doi:10.1212/wnl.54.11.2190 · Cited by 36 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Smoked cannabis for chronic neuropathic pain: a randomized controlled trial
Ware, M. A., Wang, T., Shapiro, S., Robinson, A., Ducruet, T., Huynh, T., Gamsa, A., Bennett, G. J., & Collet, J.-P. (2010) · Canadian Medical Association Journal · doi:10.1503/cmaj.091414 · Cited by 450 · see citing works
Self-citationManzanares, J., Julian, M., & Carrascosa, A. (2006) · Current Neuropharmacology · doi:10.2174/157015906778019527 · Cited by 287 · see citing works
Psychiatric Issues in Multiple Sclerosis
Chwastiak, L. A., & Ehde, D. M. (2007) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2007.07.003 · Cited by 166 · see citing works
Bell, A. D., MacCallum, C., Margolese, S., Walsh, Z., Wright, P., Daeninck, P. J., Mandarino, E., Lacasse, G., Kaur Deol, J., de Freitas, L., et al. (2024) · Cannabis & Cannabinoid Research · doi:10.1089/can.2021.0156 · Cited by 78 · see citing works
“More research is needed regarding the efficacy and safety of topical CBM.”
BackgroundInfluentialThe prevalence of anxiety and associated factors in persons with multiple sclerosis
Pham, T., Jetté, N., Bulloch, A. G. M., Burton, J. M., Wiebe, S., & Patten, S. B. (2018) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2017.11.003 · Cited by 64 · see citing works
Lynch, M. E., Young, J., & Clark, A. J. (2006) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2006.05.016 · Cited by 34 · see citing works
Self-citationGuidelines for the Use of Cannabinoid Compounds in Chronic Pain
Clark, A., Lynch, M., Ware, M., Beaulieu, P., McGilveray, I., & Gourlay, D. (2005) · Pain Research and Management · doi:10.1155/2005/894781 · Cited by 31 · see citing works
Self-citationSt-Amant, H., Ware, M. A., Julien, N., & Lacasse, A. (2015) · CMAJ Open · doi:10.9778/cmajo.20140095 · Cited by 10 · see citing works
Self-citation
- Authors
- Clark, A. J., Ware, M. A., Yazer, E., Murray, T. J., & Lynch, M. E.
- Affiliations
- Dalhousie University (CA)
- Venue
- Neurology
- Published
- 2004-06-08
- Volume
- 62
- Issue
- 11
- Pages
- 2098-2100
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2162774666
- Cited by
- 153
- References
- 12
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 7 · 2022: 3 · 2021: 7 · 2020: 8 · 2019: 5 · 2018: 9 · 2017: 9 · 2016: 8 · 2015: 13 · 2014: 3 · 2013: 7 · 2012: 10
- FWCI
- 6.70
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neurology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Multiple Sclerosis Research Studies
- Health Sciences › Medicine › Neurology › Botulinum Toxin and Related Neurological Disorders
- Keywords
- cannabis use, multiple sclerosis, medical cannabis, symptom management, prevalence, recreational cannabis, tobacco use, sex differences, pain, spasticity, sleep, mood, stress
- MeSH terms
- Administration, Oral, Adult, Cannabis, Cross-Sectional Studies, Drug Utilization, Female, Humans, Male, Phytotherapy, Middle Aged, Multiple Sclerosis, Muscle Spasticity, Nova Scotia, Pain, Patients, Surveys and Questionnaires, Sleep Wake Disorders, Smoking, Treatment Outcome, Plant Preparations
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
